netFormulary Harrogate & Rural District Formulary NHS
Harrogate & District NHS Foundation Trust
Harrogate & Rural District Clinical Commissioning Group
 
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
All Chemotherapy in HDFT is prescribed using the ChemoCare electronic prescribing system.  Only Consultants or Registrars may initiate chemotherapy.

If any patients are admitted to the Trust on oral chemotherapy the admitting doctor must contact the Oncology/Haemtology team to determine whether the treatment should be continued.

If the original prescriber is not available or cannot be contacted the oral anticancer medicine must be not be prescribed or administered until it is confirmed that it is clinically appropriate and safe to do so.

Further guidance on oral chemotherapy can be found in the Oral Anti-Cancer Medicines Handbook on the Trust Intranet.

Guidance on symptom management in palliative care can be found in The Yorkshire Cancer Network and North East Yorkshire & Humber Clinical Alliance guidelines.

Chapter Links...
 Details...
08.02.03  Expand sub section  Anti-lymphocyte monoclonal antibodies
Alemtuzumab (MabCampath)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England for the treatment of multiple sclerosis, pre-transplant immunosupression and chronic lymphocytic luekemia (CLL) 
   
Ofatumumab (Arzerra)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
Approved by the HaRD Area Prescribing Committee, March 2015 
   
Cytotoxic Drug Rituximab (Truxima)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines which are suitable to be prescribed in primary care only after specialist recommendation. Ongoing prescribing by primary care includes titration of dose and assessment of efficacy. There is no need for ongoing monitoring other than for general adverse effects as listed in the BNF & SPC.  

Amber Shared Care

Medicines which are suitable to be prescribed in primary care only after specialist recommendation only under a shared care protocol once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must be approved by the Harrogate & Rurual District Area Prescribing Committee (HaRD APC).   

Black

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) has reviewed and does not recommend for use at present based on a review of clinical and/or cost effectiveness data.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with nationally recognised formularies e.g. BNF, BNF for Children, Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Grey

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) have not yet reviewed.   

Red

Medicines for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician. The drug should be supplied by the hospital for the duration of the treatment course. Primary care prescriber initiation or continuation of treatemnt is not recommended.  

netFormulary